Rocket Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Rocket Pharmaceuticals, Inc. (RCKT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.60 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2022-11-04
- 2022-09-30: Operating Lease, Right-of-Use Asset, Amortization Expense 9 month $1.60M.
- 2021-09-30: Operating Lease, Right-of-Use Asset, Amortization Expense 9 month $0.00.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month |
|---|---|
| 2022-09-30 | $1.60M 10-Q · filed 2022-11-04 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |